Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 1999

View Archived Issues

Centocor outlines progress during second quarter

Ascent and Alpharma complete strategic alliance

Bristol-Myers Squibb highlights Q2 1999 activities

Enzo Biochem begins human trial for HBV therapy

Pilot trial commences for Eligix's BCell-HDM product

Nexell and Baxter complete transfer agreements

Genzyme General acquires Peptimmune

Acadia licenses novel leads for glaucoma therapy to Allergan

Paratek and Glaxo Wellcome to discover and develop new antibiotics

Acusphere's ultrasound contrast agent completes phase I study

Bavarian Nordic to begin phase II study of pancreatic cancer therapy

Inhibitors of 15-LO designed at Warner-Lambert, particularly useful for atherosclerosis

Aryl ureas for cytokine- and MMP-mediated conditions disclosed by Bayer

Bayer prepares selective beta3-adrenergic agents for obesity, diabetes

Amgen discloses new class of cytokine production inhibitors

Anxiolytic and anticonvulsant agents in early development at Dainippon

Novel neuroprotective compounds emerge from R&D at Snow Brand

Mochida presents potent and selective heterocyclic cGMP-PDE inhibitors

Axcan seeks merger with Scandipharm

Third-generation beta-blocker with vasorelaxant and alpha-adrenoceptor-blocking effects

Artemether/co-artemether: multiple-dose pharmacokinetics in patients with malaria

Further preclinical testing of NTE-122 supports potential in hyperlipidemia

Bextra trial terminated due to no significant survival advantage

Structurally novel 5-HT3 receptor antagonist characterized in vitro and in vivo

Connetics seeks FDA approval of scalp dermatoses treatment

FDA approves Antagon for LH inhibition in women undergoing fertility treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...